X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GNOS-PV02, a DNA plasmid-encoded PTCV in combination with DNA plasmid encoded IL-12 (a cytokine adjuvant), and pembrolizumab (a PD-1 inhibitor) in second-line (2L) patients with advanced hepatocellular carcinoma previously treated with a multi-tyrosine kinase inhibitor.
Lead Product(s): GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Product Name: GNOS-PV02
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
The net proceeds will fund completion of phase 1b/2a GT-30 Program evaluating personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in combination with Pembrolizumab (MK-3475) in subjects with advanced hepatocellular carcinoma.
Lead Product(s): GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Product Name: GNOS-PV02
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Shanghai Healthcare Capital
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 27, 2023
Details:
The net proceeds will fund expansion of Phase 1b/2a GT-30 Program. GT-30 is evaluating safety, immunogenicity, and efficacy of PTCV (GNOS-PV02 plus plasmid-encoded IL-12) in patients with unresectable or metastatic HCC.
Lead Product(s): GNOS-PV02,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Product Name: GNOS-PV02
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: 3B Future Health Fund
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 12, 2023
Details:
The proceeds will be used for the expansion of the company’s GT-30 Phase Ib/IIa clinical trial. GT-30 evaluates Geneos’ personalized cancer vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer.
Lead Product(s): GT-30,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Product Name: GNOS-PV02
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Sante Ventures
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 24, 2022
Details:
Geneos Therapeutics, Inc. has executed a new purchasing contract under their current Clinical Manufacturing Supply Agreement to support the expansion of the ongoing clinical trial for GNOS-PV02.
Lead Product(s): GT-30,INO-9012,Pembrolizumab
Therapeutic Area: Oncology Product Name: GNOS-PV02
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: VGXI
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 16, 2021
Details:
Geneos Therapeutics' personalized neoantigen-targeting vaccine, GNOS-PV02, will be evaluated in a clinical trial for patients with advanced Hepatocellular Carcinoma (HCC).
Lead Product(s): GNOS-PV02,Pembrolizumab,INO-9012
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
